Patients with diabetes are constantly being offered the technological equivalent of the latest smartphone. Trouble is, many can only afford a basic handset.
The three drugmakers that dominate the world diabetes market -- Novo Nordisk A/S, Sanofi and Eli Lilly & Co. -- are introducing improved forms of insulin, the sugar-regulating hormone some patients require, with a price tag to match. But with diabetes tearing across the developing world, health officials say the focus must return to meeting basic needs.
